Antifungal therapy – Page 10

Two Cases of Curvularia geniculata Keratitis Successfully Treated with Natamycin-Based Therapy

mycolabadmin

Two patients developed rare fungal eye infections caused by Curvularia geniculata after eye injuries from plant material. The infections caused corneal ulcers with characteristic feathery infiltrates. Both patients were successfully treated using natamycin eyedrops, either alone or combined with voriconazole, and both recovered excellent vision. Accurate identification of the fungus using genetic testing confirmed the diagnosis and helped guide treatment decisions.

Global, Regional, and National Burden of Pulmonary Fungal Infections 1990–2021

mycolabadmin

This study analyzed the global impact of fungal lung infections from 1990 to 2021, finding that about 5.6 million people were affected in 2021 with significant mortality rates. The burden of these infections is particularly high in low- and middle-income countries and affects older individuals more severely. The researchers project that deaths from fungal lung infections will double by 2044, emphasizing the need for better prevention strategies, vaccines, and international cooperation to address this growing health challenge.

Global status and trends of invasive pulmonary aspergillosis: A bibliometric study

mycolabadmin

This study analyzes 24 years of research on invasive pulmonary aspergillosis, a serious fungal infection in immunocompromised patients. Using bibliometric tools, researchers mapped out how the field has evolved, identifying leading countries (USA, Germany, China), key experts like David Denning and Thomas Walsh, and shifting research focus from transplant-related infections to COVID-19-associated cases. The analysis shows the field is rapidly growing with increasing emphasis on rapid diagnostic methods and antifungal therapies.

ABPA in post-tuberculosis lung disease: A diagnostic pitfall or genuine entity?

mycolabadmin

After tuberculosis treatment, some patients develop fungal lung infections that can look very similar to an allergic fungal disease called ABPA. This editorial warns doctors that they need to be careful about diagnosing ABPA in tuberculosis patients because treating it with the wrong medications could make the fungal infection worse. The key difference is that true ABPA causes wheezing and asthma-like symptoms, while post-TB fungal infections cause cavities and scarring in the lungs.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect shares decades of experience treating fungal infections and developing antifungal medications. He discusses how treatments have evolved from highly toxic drugs to more effective options, but notes that fungal infections remain challenging, especially when patients develop resistance or have serious underlying diseases. He emphasizes the importance of combining drugs with immune therapies and shorter, more potent treatments rather than lengthy medication courses. Despite challenges, Dr. Perfect is optimistic about the future of medicine and encourages young scientists to pursue careers in this field.

HIV protease inhibitors restore amphotericin B activity against Candida

mycolabadmin

Researchers discovered that HIV protease inhibitors, medications commonly used to treat HIV, can significantly enhance the effectiveness of amphotericin B, a powerful antifungal drug. When combined, these medications work synergistically to kill the dangerous fungus Candida auris, reduce its ability to form protective biofilms, and lower infection levels. This finding suggests a promising new treatment strategy for multidrug-resistant fungal infections that currently pose a serious global health threat.

Dual fungal endocarditis in a pediatric dialysis patient: First case of Aspergillus flavus and Candida parapsilosis co-infection

mycolabadmin

A 13-year-old boy with kidney disease requiring dialysis developed a rare dual fungal heart infection caused by two different fungi simultaneously. Doctors diagnosed the infection using heart imaging, blood tests, and tissue examination, then treated him with antifungal medications and two heart surgeries to remove infected tissue and replace a damaged heart valve. Despite the extreme rarity and severity of this condition, the patient survived, which had never been reported in children before.

Histoplasma capsulatum prosthetic valve endocarditis treated with oral isavuconazole

mycolabadmin

A 76-year-old man developed a rare fungal infection on his artificial heart valve caused by Histoplasma capsulatum, a fungus found in soil and bird droppings. After surgery to replace the infected valve, he was treated with isavuconazole, an antifungal medication that proved highly effective and better tolerated than traditional treatments. After nine months of therapy, all signs of infection had resolved and his new valve was working properly.

Successful management of Lomentospora prolificans septic arthritis and osteomyelitis in an immunocompetent child: A case report

mycolabadmin

A 3-year-old boy developed a serious fungal bone and joint infection caused by Lomentospora prolificans after surgery to fix a broken elbow. This fungus is extremely resistant to most antifungal medications. The infection was successfully treated using multiple approaches: aggressive surgical cleaning, several different antifungal drugs used together, special antibiotic-loaded bone cement, and antiseptic rinses. After two months of intensive treatment, the infection cleared and the child’s arm was saved from amputation.

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections are becoming a major health threat, affecting over a billion people worldwide. The main problems are difficulty diagnosing these infections, increasing resistance to current medications, and limited treatment options. Doctors and the public need better awareness, and new antifungal drugs with different approaches are needed to effectively treat resistant infections.

Research Topic: Antifungal therapy